Insulet Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Insulet şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.08%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.08%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines

Nov 20

Does This Valuation Of Insulet Corporation (NASDAQ:PODD) Imply Investors Are Overpaying?

Nov 20

Additional Considerations Required While Assessing Insulet's (NASDAQ:PODD) Strong Earnings

Aug 16

A Look At The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Jul 15

Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023

Jun 11

We Like These Underlying Return On Capital Trends At Insulet (NASDAQ:PODD)

May 26

At US$166, Is It Time To Put Insulet Corporation (NASDAQ:PODD) On Your Watch List?

May 12

Is Insulet (NASDAQ:PODD) A Risky Investment?

Apr 29

Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors

Apr 14

Estimating The Fair Value Of Insulet Corporation (NASDAQ:PODD)

Mar 31

Insulet: Insulating Patients, Investors Still Have To Wait

Mar 28

Insulet (NASDAQ:PODD) Is Doing The Right Things To Multiply Its Share Price

Feb 19

Is Insulet Corporation (NASDAQ:PODD) Potentially Undervalued?

Jan 22

Insulet: An Interesting, Yet Expensive, Story

Jan 10

Is Insulet (NASDAQ:PODD) Using Too Much Debt?

Jan 09

Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors

Dec 27

Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Nov 14

Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue

Oct 31

We Think Insulet (NASDAQ:PODD) Is Taking Some Risk With Its Debt

Oct 01

Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?

Sep 16

Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Aug 14

Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger

Jul 31

Is Insulet (NASDAQ:PODD) Using Too Much Debt?

Jun 18

Getting In Cheap On Insulet Corporation (NASDAQ:PODD) Might Be Difficult

May 22

Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger

Apr 30

Here's Why Insulet (NASDAQ:PODD) Has A Meaningful Debt Burden

Jan 24

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: PODD şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: PODD şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Insulet Piyasaya Karşı Temettü Getirisi

PODD temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (PODD)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (PODD) (3 yıla kadar)	0%

Önemli Temettü: PODD şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, PODD şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: PODD şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: PODD herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Insulet Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines

Does This Valuation Of Insulet Corporation (NASDAQ:PODD) Imply Investors Are Overpaying?

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Returns At Insulet (NASDAQ:PODD) Are On The Way Up

Omnipod 5 App for Iphone Now Fully Available in the United States

Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues

Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?

Insulet Corporation to Report Q3, 2024 Results on Nov 07, 2024

Independent Chairman recently sold US$1.1m worth of stock

Independent Chairman notifies of intention to sell stock

Is Insulet (NASDAQ:PODD) A Risky Investment?

Insulet: Turning More Constructive, Valuations Still Stretched

Here's Why We Think Insulet (NASDAQ:PODD) Is Well Worth Watching

Insulet Corporation Announces Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

Additional Considerations Required While Assessing Insulet's (NASDAQ:PODD) Strong Earnings

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

A Look At The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Insulet Corporation to Report Q2, 2024 Results on Aug 08, 2024

Now 9.0% overvalued after recent price rise

Now 20% overvalued after recent price rise

Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes

Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

Independent Chairman recently sold US$1.3m worth of stock

Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023

Independent Chairman notifies of intention to sell stock

We Like These Underlying Return On Capital Trends At Insulet (NASDAQ:PODD)

Investor sentiment improves as stock rises 16%

At US$166, Is It Time To Put Insulet Corporation (NASDAQ:PODD) On Your Watch List?

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Is Insulet (NASDAQ:PODD) A Risky Investment?

Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors

Insulet Corporation, Annual General Meeting, May 22, 2024

Insulet Corporation to Report Q1, 2024 Results on May 09, 2024

Estimating The Fair Value Of Insulet Corporation (NASDAQ:PODD)

Insulet: Insulating Patients, Investors Still Have To Wait

Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024

Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial (RCT) Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5)

Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes

Director & Advisor notifies of intention to sell stock

Consensus EPS estimates increase by 18%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024

Insulet (NASDAQ:PODD) Is Doing The Right Things To Multiply Its Share Price

Is Insulet Corporation (NASDAQ:PODD) Potentially Undervalued?

Insulet Corporation Announces Board Changes

Insulet Corporation to Report Q4, 2023 Results on Feb 22, 2024

Insulet: An Interesting, Yet Expensive, Story

Is Insulet (NASDAQ:PODD) Using Too Much Debt?

Insulet Corporation's (NASDAQ:PODD) Earnings Haven't Escaped The Attention Of Investors

Director & Advisor recently sold US$2.5m worth of stock

Director & Advisor notifies of intention to sell stock

Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Consensus EPS estimates increase by 13%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Provides Revenue Guidance for the Fourth Quarter and Year Ending December 31, 2023

Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue

Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone

Price target decreased by 8.0% to US$250

Now 21% undervalued after recent price drop

Insulet Corporation Announces CFO Transition

We Think Insulet (NASDAQ:PODD) Is Taking Some Risk With Its Debt

Insulet Corporation to Report Q3, 2023 Results on Nov 02, 2023

Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?

Insulet Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System in Germany

Consensus EPS estimates increase by 14%

Estimating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger

Insulet Corporation to Report Q2, 2023 Results on Aug 08, 2023

Insulet Corporation Announces Omnipod 5 Automated Insulin Delivery System Is Now Available in the United Kingdom

Is Insulet (NASDAQ:PODD) Using Too Much Debt?

Insider recently bought US$1.0m worth of stock

Getting In Cheap On Insulet Corporation (NASDAQ:PODD) Might Be Difficult